Cargando…

Clinical predictors for sessile serrated polyposis syndrome: A case control study

AIM: To compared individuals with serrated polyposis syndrome (SPS) to those with sessile serrated adenoma (SSA) and adenomas in the setting of endoscopists with high adenoma detection rates at a secondary and tertiary academic centre. METHODS: Retrospectively we collated the clinical, endoscopic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yang, Mullin, Alexander, Stoita, Alina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605346/
https://www.ncbi.nlm.nih.gov/pubmed/28979711
http://dx.doi.org/10.4253/wjge.v9.i9.464
_version_ 1783264972349898752
author Wu, Yang
Mullin, Alexander
Stoita, Alina
author_facet Wu, Yang
Mullin, Alexander
Stoita, Alina
author_sort Wu, Yang
collection PubMed
description AIM: To compared individuals with serrated polyposis syndrome (SPS) to those with sessile serrated adenoma (SSA) and adenomas in the setting of endoscopists with high adenoma detection rates at a secondary and tertiary academic centre. METHODS: Retrospectively we collated the clinical, endoscopic and histological features of all patients with SPS at St Vincent’s public and private hospital in the last 3 years. Patients were identified by searching through 2 pathology databases. Variables explored included smoking status, symptoms, and family history of concurrent colorectal cancer, number and location of polyps. Patients with SPS were matched to two cohorts (1) patients with SSA not meeting World Health Organization (WHO) criteria for SPS over 3 years; and (2) patients with exclusively adenomas. The control cases were also matched according to gender and endoscopist. Adenoma detection rates ranged from 25% to 40%. RESULTS: Forty patients with SPS were identified and matched with 40 patients in each control group. In total 15452 colonoscopies were performed over the study period which amounts to a prevalence of 1: 384 patients (0.26%) with SPS. Fourteen patients (35%) required more than 1 year to accumulate enough polyps to reach WHO criteria for SPS. The diagnosis of SPS was largely incidental and 5% SPS patients were diagnosed with colorectal cancer over 3 years. The chance of detecting a meta-synchronous adenoma was similar in those with SPS (42%) and those with SSA (55%), P = 0.49. The majority of patients (75%) meeting criteria for SPS were women. The mean age of those with SPS (45 years) was significantly lower than both cohorts with SSA (57 years) and adenomas (63 years), P = 0.01. On univariate analysis cigarette exposure, first-degree family history of colorectal cancer and a high BMI weren’t significantly more associated with SPS compared to patients with SSA or patients with adenomas. However, patients with SPS (97%) and patients with SSAs not meeting SPS criteria (98%) were significantly more likely to be Caucasian compared to patients with adenomas (79%), P = 0.01. CONCLUSION: The prevalence of SPS in our study was 0.26%. The vast majority of patients diagnosed with SPS were women. As a group, they were significantly younger compared to patients with SSA not meeting WHO criteria and patients with adenomatous polyps by more than a decade. Patients with SPS were no more likely to have a first degree relative with colorectal cancer or smoking history than the other two groups. Patients with serrated polyps were more likely to be Caucasian than patients with adenomas.
format Online
Article
Text
id pubmed-5605346
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-56053462017-10-04 Clinical predictors for sessile serrated polyposis syndrome: A case control study Wu, Yang Mullin, Alexander Stoita, Alina World J Gastrointest Endosc Case Control Study AIM: To compared individuals with serrated polyposis syndrome (SPS) to those with sessile serrated adenoma (SSA) and adenomas in the setting of endoscopists with high adenoma detection rates at a secondary and tertiary academic centre. METHODS: Retrospectively we collated the clinical, endoscopic and histological features of all patients with SPS at St Vincent’s public and private hospital in the last 3 years. Patients were identified by searching through 2 pathology databases. Variables explored included smoking status, symptoms, and family history of concurrent colorectal cancer, number and location of polyps. Patients with SPS were matched to two cohorts (1) patients with SSA not meeting World Health Organization (WHO) criteria for SPS over 3 years; and (2) patients with exclusively adenomas. The control cases were also matched according to gender and endoscopist. Adenoma detection rates ranged from 25% to 40%. RESULTS: Forty patients with SPS were identified and matched with 40 patients in each control group. In total 15452 colonoscopies were performed over the study period which amounts to a prevalence of 1: 384 patients (0.26%) with SPS. Fourteen patients (35%) required more than 1 year to accumulate enough polyps to reach WHO criteria for SPS. The diagnosis of SPS was largely incidental and 5% SPS patients were diagnosed with colorectal cancer over 3 years. The chance of detecting a meta-synchronous adenoma was similar in those with SPS (42%) and those with SSA (55%), P = 0.49. The majority of patients (75%) meeting criteria for SPS were women. The mean age of those with SPS (45 years) was significantly lower than both cohorts with SSA (57 years) and adenomas (63 years), P = 0.01. On univariate analysis cigarette exposure, first-degree family history of colorectal cancer and a high BMI weren’t significantly more associated with SPS compared to patients with SSA or patients with adenomas. However, patients with SPS (97%) and patients with SSAs not meeting SPS criteria (98%) were significantly more likely to be Caucasian compared to patients with adenomas (79%), P = 0.01. CONCLUSION: The prevalence of SPS in our study was 0.26%. The vast majority of patients diagnosed with SPS were women. As a group, they were significantly younger compared to patients with SSA not meeting WHO criteria and patients with adenomatous polyps by more than a decade. Patients with SPS were no more likely to have a first degree relative with colorectal cancer or smoking history than the other two groups. Patients with serrated polyps were more likely to be Caucasian than patients with adenomas. Baishideng Publishing Group Inc 2017-09-16 2017-09-16 /pmc/articles/PMC5605346/ /pubmed/28979711 http://dx.doi.org/10.4253/wjge.v9.i9.464 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Case Control Study
Wu, Yang
Mullin, Alexander
Stoita, Alina
Clinical predictors for sessile serrated polyposis syndrome: A case control study
title Clinical predictors for sessile serrated polyposis syndrome: A case control study
title_full Clinical predictors for sessile serrated polyposis syndrome: A case control study
title_fullStr Clinical predictors for sessile serrated polyposis syndrome: A case control study
title_full_unstemmed Clinical predictors for sessile serrated polyposis syndrome: A case control study
title_short Clinical predictors for sessile serrated polyposis syndrome: A case control study
title_sort clinical predictors for sessile serrated polyposis syndrome: a case control study
topic Case Control Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605346/
https://www.ncbi.nlm.nih.gov/pubmed/28979711
http://dx.doi.org/10.4253/wjge.v9.i9.464
work_keys_str_mv AT wuyang clinicalpredictorsforsessileserratedpolyposissyndromeacasecontrolstudy
AT mullinalexander clinicalpredictorsforsessileserratedpolyposissyndromeacasecontrolstudy
AT stoitaalina clinicalpredictorsforsessileserratedpolyposissyndromeacasecontrolstudy